The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer
about
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to TherapyLet-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysisSNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancerNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.SNPs in microRNA binding sites as prognostic and predictive cancer biomarkersLet-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabActivation of KRAS promotes the mesenchymal features of basal-type breast cancer.Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.KRAS Gene Polymorphisms and their Impact on Breast Cancer Risk in an Iranian Population
P2860
Q26801487-C9183740-64A1-480E-A26B-9E4FEDB7C3CBQ26827474-A5A0D292-14CB-423D-BDAC-7B9CDFB1FD49Q26829794-55C8BFC0-5FC5-4241-89A1-0D51BA76CB97Q30374367-42515E46-184A-4C45-B33D-A0391AC291FAQ33640984-2DE0E2F3-D872-4285-9F6A-37A83846F2F8Q34483581-0F5842BD-6579-4B4E-A994-BDA2C101DAE0Q35040663-7E9ADB0B-B458-4343-ADA2-A37B2A8636FDQ36187913-6D7B280C-C483-40A9-A489-D559F2C7C365Q36228676-BA46E355-F73F-4D0D-94BF-CF010B97FE95Q37420213-3EDEE71B-9F59-43FD-A829-44EFAC1006B8Q38383212-C0641EC4-F3EE-4ADA-B687-B73B78A95B45Q40277712-3B3F07FD-563E-4226-A36C-D278ABE9D23EQ40492655-A8DA3BA2-7D94-4B88-9B71-87FD47B70AD3Q41381748-2A01CC5E-3EC7-4FDF-B7FE-F0AC1C4167DE
P2860
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The KRAS-variant is associated ...... mary breast and ovarian cancer
@ast
The KRAS-variant is associated ...... mary breast and ovarian cancer
@en
The KRAS-variant is associated ...... mary breast and ovarian cancer
@nl
type
label
The KRAS-variant is associated ...... mary breast and ovarian cancer
@ast
The KRAS-variant is associated ...... mary breast and ovarian cancer
@en
The KRAS-variant is associated ...... mary breast and ovarian cancer
@nl
prefLabel
The KRAS-variant is associated ...... mary breast and ovarian cancer
@ast
The KRAS-variant is associated ...... mary breast and ovarian cancer
@en
The KRAS-variant is associated ...... mary breast and ovarian cancer
@nl
P2093
P2860
P50
P1433
P1476
The KRAS-variant is associated ...... mary breast and ovarian cancer
@en
P2093
Daniel Zelterman
Divya A Patel
Jemima J Dorairaj
Lee P Shulman
Megan McKenna
Michael J Kerin
Michelle Hildebrandt
Nicola Miller
Robert Pilarski
Sharon Sand
P2860
P304
P356
10.1371/JOURNAL.PONE.0037891
P407
P577
2012-01-01T00:00:00Z